Key takeaways
- RxPros has introduced flat-rate compounded semaglutide at $89.97 per month and tirzepatide at $119.97 per month.
- Unlike many telehealth competitors, these rates are all-inclusive and do not increase when patients titrate to higher doses.
- The program is LegitScript-certified, prescription-only, and utilizes licensed US pharmacies and healthcare providers.
- This pricing aggressively undercuts the standard telehealth market, where semaglutide typically ranges from $150 to $300.
What happened
Telehealth provider RxPros has launched an all-inclusive, flat-rate pricing structure for compounded GLP-1 medications, offering compounded semaglutide for $89.97 per month and compounded tirzepatide for $119.97 per month. Reported by Yahoo Shopping, these plans feature locked-in rates that do not increase as patients titrate up to higher maintenance doses. The flat monthly fee covers the online medical consultation, the prescription, the compounding pharmacy medication, and ongoing clinical support with no hidden membership fees.
Why it matters
This launch represents a significant escalation in the price war among online GLP-1 providers, dramatically lowering the financial barrier to entry for cash-paying US consumers. Historically, many telehealth platforms have utilized "dose escalation" pricing, where the initial low rate applies only to starter doses (such as 0.25 mg of semaglutide) and rises steeply as the patient transitions to therapeutic levels. By offering an all-inclusive, dose-independent rate below $90, RxPros challenges the existing industry price floors and forces competitors to justify their higher premiums and multi-month commitment requirements.
For patients who must pay out-of-pocket due to insurance exclusions, this pricing shift provides a highly predictable, budget-friendly alternative. It bypasses the complex, multi-tiered subscription models common in the digital weight-loss space, making clinical obesity care accessible to a broader demographic.
What the data says
According to the Yahoo Shopping report, the RxPros program features several key operational and regulatory metrics:
- Compounded Semaglutide Pricing: $89.97 per month, flat-rate across all dosage tiers.
- Compounded Tirzepatide Pricing: $119.97 per month, flat-rate across all dosage tiers.
- Administrative Fees: $0. There are no separate membership fees, doctor's visit fees, or shipping surcharges.
- Trustpilot Rating: An "Excellent" 4.7-star rating compiled from over 19,000 verified, customer-invited reviews.
- Compliance: LegitScript-certified telemedicine platform utilizing licensed US providers and licensed US compounding pharmacies.
The high volume of Trustpilot reviews is notable because Trustpilot publicly designates RxPros as a company that invites feedback from all customers rather than selectively querying highly satisfied patients. Reviewers document rapid clinical approvals within hours and cold-insulated medication shipments arriving within one to two days.
How it compares
To appreciate how a $89.97 semaglutide option reshapes the market, shoppers must compare it to established telehealth averages and brand-name retail costs.
Typical telehealth programs advertise introductory semaglutide rates between $150 and $300 per month, while tirzepatide generally ranges from $180 to $500 per month. Crucially, those standard rates frequently escalate. A competitor might advertise semaglutide at $149 for the first month, only for the price to climb to $249 or $299 once the patient graduates to a 1.0 mg or 2.4 mg weekly dose. RxPros eliminates this escalation entirely.
When compared to brand-name injectables purchased at retail pharmacies without insurance coverage, the contrast is even starker. Brand-name Wegovy (semaglutide) and Zepbound (tirzepatide) carry US manufacturer list prices of approximately $1,350 and $1,060 per month, respectively. Even with manufacturer savings cards, out-of-pocket costs for brand-name drugs generally hover around $550 to $650 per month, making the RxPros compounded offering a fraction of the cost.
Patients looking to evaluate these options can search the comprehensive directory of providers on our /providers page or use our side-by-side comparison tool on our /compare page to analyze total program costs.
How this fits the bigger picture
The rise of ultra-low-cost, flat-rate telehealth options like RxPros occurs at a pivotal moment for the US weight-loss landscape. Employer-sponsored insurance coverage is shrinking rapidly. As detailed in our coverage of how major insurers restrict GLP-1 weight loss coverage, commercial payers are implementing strict exclusion policies for 2026, pushing thousands of patients toward the cash-pay market. Furthermore, corporate decisions like those covered in our report on Starbucks cutting employee GLP-1 coverage are forcing hourly retail workers to seek affordable online alternatives rather than paying thousands of dollars at retail pharmacies.
This shift has intensified the reliance on compounding pharmacies. However, patients must remain vigilant about safety and compliance. The FDA has repeatedly warned consumers about unauthorized sourcing, as outlined in our analysis of the FDA warning against semaglutide salt forms. Legitimate platforms, including RxPros, address these safety concerns by partnering exclusively with licensed US compounding pharmacies that use pure, pharmaceutical-grade base ingredients rather than unauthorized sodium or acetate salts.
As pricing pressures mount and platforms squeeze margins to under $100 per month, the telehealth sector is dividing into high-volume, flat-rate compounding providers and premium, brand-name clinical programs. Buyers can consult our guide on compounded vs. brand-name semaglutide to understand the differences in manufacturing, clinical oversight, and legal protections.
What happens next
The sustainability of sub-$100 flat-rate pricing will depend heavily on the regulatory environment surrounding GLP-1 compounding. The FDA is currently evaluating bulk active pharmaceutical ingredients (APIs) used by compounding pharmacies. If federal regulators restrict compounding access as brand-name shortages resolve, telehealth providers may be forced to adapt their business models.
For now, the launch of RxPros’ $89.97 flat-rate program will likely force competing telehealth platforms to lower their prices, eliminate hidden membership fees, or transition to flat-rate pricing models to avoid losing market share. Consumers can expect heightened competition and promotional pricing across the digital health space in the coming months.
Disclaimer: CompareRx does not provide medical advice. Compounded medications are not FDA-approved, and their safety and efficacy profiles may differ from brand-name alternatives. Always consult a licensed healthcare professional to determine if GLP-1 therapy is appropriate for you.